Active substanceChondroitin sulfateChondroitin sulfate
Similar drugsTo uncover
  • Artogistan
    solution w / m 
    GROTEKS, LLC     Russia
  • ARTRA® Chondroitin
    capsules inwards 
    Unipharm, Inc.     USA
  • Arthravir®-Inkamparm®
    solution w / m 
    TRIVIUM-XXI, LLC     Russia
  • Arthradol®
    lyophilizate w / m 
    Inkamfarm, OOO     Russia
  • ARTRADOL®
    capsules inwards 
    TRIVIUM-XXI, LLC     Russia
  • Artrafic
    ointment externally 
    ATOLL, LLC     Russia
  • DRASTOP
    solution w / m 
  • Mukosat®
    solution w / m 
  • Mukosat®
    ointment externally 
       
  • Teraflex® Hondrokrem Forte
    cream externally 
    BAYER, AO     Russia
  • Hondroguard®
    solution w / m 
  • Chondroitin
    capsules inwards 
    VERTEKS, AO     Russia
  • Chondroitin
    gel externally 
    VERTEKS, AO     Russia
  • Chondroitin
    capsules inwards 
    ATOLL, LLC     Russia
  • Chondroitin sulfate
    lyophilizate w / m 
    ELLARA, LTD.     Russia
  • Chondroitin-Akos
    ointment externally 
    SYNTHESIS, OJSC     Russia
  • Chondroitin-Akos
    capsules inwards 
    SYNTHESIS, OJSC     Russia
  • Chondroitin sulfate
    solution w / m 
    Medimeks, ZAO     Russia
  • Chondroitin sulfate
    solution w / m 
    ELLARA, LTD.     Russia
  • Chondroitin sulfate
    lyophilizate w / m 
  • Chondroitin sulfate
    solution w / m 
    BIOSINTEZ, PAO     Russia
  • Chondroxide®
    ointment externally 
    NIZHFARM, JSC     Russia
  • Chondroxide®
    pills inwards 
    NIZHFARM, JSC     Russia
  • Chondroxide®
    gel externally 
    NIZHFARM, JSC     Russia
  • Chondrolon®
    lyophilizate w / m 
  • Dosage form: & nbsp
    Gel for external use.
    Composition:
    In 1 g of gel contains:
    active substance: chondroitium sulphate - 50.0 mg;
    Excipients: dimethylsulfoxide - 75.0 mg; propylene glycol 75.0 mg; carbomer - 30.0 mg; trolamine (triethanolamine) 30.0 mg; macrogol glyceryl hydroxy stearate - 4.0 mg; disodium edetate 1.0 mg; methyl parahydroxybenzoate methyl paraben, nipagin) 1.0 mg; lavender oil - 1.0 mg; orange flowers oil (neroli oil) - 0.5 mg; purified water - up to 1.0 g.
    Description:Colorless or with a light yellow tinge transparent gel with a specific odor. Opalescence and the presence of air bubbles are acceptable.
    Pharmacotherapeutic group:Reparation of tissue stimulant.
    ATX: & nbsp

    M.01.A.X.25   Chondroitin sulfate

    Pharmacodynamics:
    Chondroitium sulfate is a high molecular weight mucopolysaccharide that slows the resorption of bone tissue and reduces the loss of calcium ions (Ca2 +). It improves the phosphorus-calcium metabolism in the cartilaginous tissue, accelerates the processes of its restoration, inhibits the processes of degeneration of the cartilaginous and connective tissue.Suppresses enzymes that cause damage to cartilaginous tissue, stimulates the synthesis of glycosaminoglycans, promotes the regeneration of the articular bag and the cartilaginous surfaces of the joints, increases the production of intra-articular fluid. Due to its structural affinity for heparin, it prevents the formation of fibrin clots in the synovial and subchondral microcirculatory bed. Reduces soreness and increases the mobility of affected joints.
    Slows the progression of osteoarthritis and osteochondrosis.
    Dimethyl sulfoxide, which is part of the drug, promotes better penetration of chondroitin through cell membranes.
    Pharmacokinetics:According to the data obtained in experimental studies in mice using radiolabelled ZN-chondroitin sulfate, the chondroitin sulfate absorption index is 14%.
    Chondroitin sulfate after application of the gel to the skin quickly and selectively enters the joint with reaching a maximum concentration after 30 minutes and the subsequent biphasic excretion of the drug from the cartilage tissue. Completion of the rapid phase of withdrawal occurs 1 hour after application.The retention time of the drug in the joint is 5 hours.
    Indications:Degenerative and dystrophic diseases of the joints and spine: treatment of osteochondrosis prevention, osteoarthrosis of peripheral joints and spine.
    Contraindications:
    hypersensitivity to the components of the drug;
    - violation of the integrity of the skin in places of intended application.
    Carefully:
    - Pregnancy;
    - the period of breastfeeding;
    - Children under 18 years of age (efficacy and safety not established).
    Pregnancy and lactation:

    Pregnancy

    Due to the lack of data on the safety of the drug during pregnancy, the use of the drug during this period is possible only if the intended benefit for the mother exceeds the potential risk to the fetus.

    Breastfeeding period

    There are no clinical data on the use of the drug in breast-feeding women.

    Dosing and Administration:
    Outwardly.
    Apply 2-3 times a day on the skin over the lesion and rub for 2-3 minutes until completely absorbed. The course of treatment is from 2-3 weeks to 2 months. If necessary, repeat the treatment.
    Side effects:Allergic reactions.
    Overdose:No cases of chondroitin overdose have been reported.
    Interaction:Cases of interaction or incompatibility with other drugs are not known.
    Special instructions:Avoid getting the gel on the mucous membranes and open wounds. Upon contact with skin or clothing, the gel is easily washed off with water, leaving no residue. Do not use the drug without consulting a doctor during pregnancy, during breastfeeding and in childhood.
    Effect on the ability to drive transp. cf. and fur:The drug does not affect the ability to perform potentially dangerous activities requiring increased concentration of attention and speed of psychomotor reactions (vehicle management, work with moving mechanisms).
    Form release / dosage:
    Gel for external use 5%.
    Packaging:
    30 g and 50 g in aluminum tubes.
    Each tube together with the instruction for use is swept into a pack of cardboard.
    Storage conditions:Store at a temperature not exceeding 25 ° C. Keep out of the reach of children.
    Shelf life:2 years. Do not use after expiry date.
    Terms of leave from pharmacies:Without recipe
    Registration number:LSR-002088/08
    Date of registration:25.03.2008
    The owner of the registration certificate:VERTEKS, AO VERTEKS, AO Russia
    Manufacturer: & nbsp
    Information update date: & nbsp07.10.2015
    Illustrated instructions
      Instructions
      Up